[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

Phase 1, Open-label, Study of Voruciclib in Subjects With Relapsed and/or Refractory B Cell Malignancies or AML After Failure of Prior Standard Therapies and Voruciclib in Combination With Venetoclax in Subjects With Relapsed/Refractory AML


Description

This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combination with venetoclax in subjects with relapsed or refractory AMLThis is a Phase 1, open-label, 3 + 3 dose escalation and expansion study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of prior standard therapies or voruciclib in combination with venetoclax in subjects with relapsed or refractory AML. Escalation to the next higher dose level will depend on demonstrated safety and tolerability at each dose level.

Trial Eligibility

Inclusion Criteria: * Age ≥18 years * Histologically-confirmed diagnosis of Follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia(CLL), diffuse large B-cell lymphoma (DLBCL), or AML a. Subjects must have disease that has relapsed or is refractory to 2 or more prior regimens and in need of treatment due to progressive disease * Presence of measurable disease defined per the 2008 International workshop on CLL guidelines, or by 2014 Lugano criteria for non-Hodgkin lymphoma (does not apply for AML subjects) * Adequate hematologic parameters unless clearly due to the disease under study * Adequate renal and hepatic function, per laboratory reference range at screening Exclusion Criteria: * History of pneumonitis of any cause * For CLL subjects: only known histological transformation to an aggressive lymphoma * For AML subjects: 1. Acute promyelocytic leukemia 2. Peripheral blast count \> 25 × 10 9/L * Known central nervous system involvement * Significant cardiovascular disease * Significant screening ECG abnormalities * Subjects who require warfarin, anti-cancer therapeutics or investigational agents * Evidence of an ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections) at the time of start of voruciclib therapy * Prior solid organ transplantation * Receipt of an allogeneic transplant within 6 months or an autologous transplant within the preceding 3 months; evidence of ongoing graft-versus-host disease (GVHD) * Prior therapy with a cyclin-dependent kinase (CDK9) inhibitor * Symptomatic/uncontrolled HIV infection/AIDS, or currently taking contraindicated medications for HIV control * Ongoing immunosuppressive treatment including calcineurin inhibitors at the time of the start of study treatment, including systemic or enteric corticosteroids except as follows: 1. Prior to the start of study treatment, subjects may be using systemic corticosteroids (≤20 mg/day of prednisone or equivalent), topical, or inhaled corticosteroids 2. During study therapy, subjects may use systemic, topical, or enteric corticosteroids, if needed

Study Info

Organization

MEI Pharma, Inc.


Primary Outcome

Determine the safety and tolerability of voruciclib


Outcome Timeframe 2 years

NCTID NCT03547115

Phases PHASE1

Primary Purpose TREATMENT

Start Date 2018-05-31

Completion Date 2024-04-30

Enrollment Target 100

Interventions

DRUG voruciclib monotherapy

DRUG voruciclib and venetoclax

Locations Recruiting

City of Hope

United States, California, Duarte


Northwestern Memorial Hospital

United States, Illinois, Chicago


Dana Farber Cancer Institute

United States, Massachusetts, Boston


Mayo Clinic

United States, Minnesota, Rochester


University of Nebraska Medical Center

United States, Nebraska, Omaha


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Diffuse Large B Cell Lymphoma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.

Thanks to our HealthTree Community for Diffuse Large B Cell Lymphoma Sponsors:

Regeneron
Bristol Myers Squibb

Follow Us

facebook instagram youtube